Future perspectives of the pharmacological management of diabetic dyslipidemia

Patti, Angelo Maria; Giglio, Rosaria Vincenza; Παπάνας, Νικόλαος; Rizzo, Manfredi; Rizvi, Ali A.

doi:10.1080/17512433.2019.1567328

Cited by 43 publications

(31 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dyslipidemia and hypertension, associated with obesity and insulin resistance, are often present in the prediabetic period of T2DM, which may account for the comorbidity of cardiovascular disease and diabetes [171,172]. T2DM dyslipidemia is characterized by increased triglycerides and LDL-C and reduced HDL-C levels [173,174]. Evidence suggests that cholesterol-lowering therapy reduces cardiovascular risk in diabetic patients [174,175]; however, low HDL-C likely contributes to diabetes as well as cardiovascular disease [173].…”

Section: Vascular Protectionmentioning

confidence: 99%

“…T2DM dyslipidemia is characterized by increased triglycerides and LDL-C and reduced HDL-C levels [173,174]. Evidence suggests that cholesterol-lowering therapy reduces cardiovascular risk in diabetic patients [174,175]; however, low HDL-C likely contributes to diabetes as well as cardiovascular disease [173]. Thus, lowering total cholesterol while restoring HDL-C would be most beneficial for treating diabetes-associated cardiovascular diseases and VaD.…”

Section: Vascular Protectionmentioning

confidence: 99%

See 1 more Smart Citation

Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review

Shinjyo

Parkinson

Bell

et al. 2020

Journal of Integrative Medicine

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Vascular Protectionmentioning

confidence: 99%

Section: Vascular Protectionmentioning

confidence: 99%

Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review

Shinjyo

Parkinson

Bell

et al. 2020

Journal of Integrative Medicine

View full text Add to dashboard Cite

show abstract

“…Contrary to hypothyroidism, uncontrolled diabetes leads to hypertriglyceridaemia and features of atherogenic dyslipidaemia [14]. Despite statin therapy, it is estimated that as many as 50% of patients with diabetes have increased level of TG [15].…”

Section: Poorly Controlled Diabetesmentioning

confidence: 99%

Endocrine diseases as causes of secondary hyperlipidemia

Bułdak

Marek

Kajdaniuk

et al. 2019

Endokrynologia Polska

View full text Add to dashboard Cite

Cardiovascular diseases are among the leading causes of increased morbidity and mortality in developed and developing countries. One of the most important risk factors responsible for atherosclerosis and subsequent cardiovascular diseases is hyperlipidaemia. Currently, hyperlipidaemias are divided into several clinical entities. The greatest risk is associated with hypercholesterolaemia. As a result, modern guidelines for the treatment and prevention of atherosclerosis focus predominantly on the reduction of LDL-cholesterol. Hypertriglyceridaemia and atherogenic dyslipidaemia, which are responsible for a less significant increase in the cardiovascular risk, are nowadays secondary targets of the treatment. During the work-up for hyperlipidaemia one of the essential actions is the exclusion of secondary causes of the lipid abnormalities. Those include, among others, endocrine diseases, diabetes, drugs, nephrotic syndrome, and pregnancy. Data regarding the impact of endocrine disease and diabetes on the lipid profile are scattered. In this review, the authors aimed to perform a thorough analysis of the available publications regarding the topic and the preparation of a comprehensive review dealing with the incidence, clinical features, and the therapy of hyperlipidaemias in patients with endocrine disease.

show abstract

“…About half of the diabetic patients suffer with these complications. 2 Diabetes mellitus causes important changes such as dyslipidemia, and disturbance in the metabolism of lipids, carbohydrates, and proteins. 3,4 it is reported that by the year of 2015, cardiovascular artery disease will be responsible for 20 million deaths approximately, mainly from strokes and heart attacks.…”

Section: Introductionmentioning

confidence: 99%

Role of simvastatin and allium sativum on lipid profile in diabetic dyslipidemic patients: a comparative study.

Siddiqui

Taj

Ishaque

et al. 2020

TPMJ

View full text Add to dashboard Cite

Objectives: To evaluate the changes in lipid profile in patients with diabetic dyslipidemia using lipid lowering drug, simvastatin and herbal product allium sativum. Study Design: Clinical trial. Setting: Surgeon Munawar Memorial Hospital, Karachi. Period: 1st January 2017 to 30th April 2017. Material & Methods: The study was designed to assess the effects of hmg-coa reductase inhibitor (simvastatin) and allium sativum on lipid profile in patients with diabetic dysplipidemia. The exclusion criteria included lactating/pregnant women’s, renal, liver and established coronary artery disease. Results: Sixty patients with abnormal lipid profile were included in the study (age 30-60 years). Patients were divided into two groups (30 patients each). Group a was orally administered with product of simvastatin (20 mg)/day for 04 months and in group b, patients were orally administered with herbal product of allium sativum (300 mg)/day for 04 months. Conclusion: On the basis of this study it is observed that allium sativum as well as simvastatin tablets both reduce total cholesterol, low density lipoprotein cholesterol (ldl-c) and increase high density lipoprotein cholesterol (hdl-c).

show abstract

Future perspectives of the pharmacological management of diabetic dyslipidemia

Cited by 43 publications

References 146 publications

Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review

Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review

Endocrine diseases as causes of secondary hyperlipidemia

Role of simvastatin and allium sativum on lipid profile in diabetic dyslipidemic patients: a comparative study.

Contact Info

Product

Resources

About